Grifols SA (GRF):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Grifols SA (GRF) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7449
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:76
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スペイン
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Grifols SA (Grifols) focuses at improving the health and well-being of people around the world. It carries out the research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. The company specializes in the production of plasma-derived medicines and has plasma donation centers across the US. Grifols provides a wide range of transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. It produces plasma derived protein therapies for patients suffering with rare, genetic diseases and life-threatening infections. The company offers its products to hospitals, pharmacies and healthcare professionals. Grifols is headquartered in Sant Cugat del Valles, Barcelona, Spain.

Grifols SA (GRF) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Grifols SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Grifols SA, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Grifols SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Grifols SA, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Grifols SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Grifols SA, Medical Equipment, Deal Details 11
Asset Purchase 11
Grifols Acquires Nucleic Acid Testing Donor Screening Unit from Hologic for USD1.85 Billion 11
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 13
Partnerships 15
Singulex Enters into Licensing Agreement with Grifols 15
Grifols and Beckman Coulter Enter into Distribution Agreement 16
Grifols Enters Into Licensing Agreement With Aradigm 17
Equity Offering 18
Grifols Invests USD50 Million in Singulex 18
TiGenix Completes Private Placement Of Shares For US$16.2 Million 19
Debt Offering 20
Grifols Raises USD1.06 Billion in Public Offering of 3.2% Bonds Due 2025 20
Grifols Completes Public Offering Of Bonds Due 2022 For US$1 Billion 21
Acquisition 22
Grifols Acquires Additional 40% Stake in Kiro Grifols for USD15 Million 22
Grifols Acquires Additional 32.93% Stake in Progenika Biopharma for USD27 Million 23
Grifols Acquires 50% Stake in Kiro Robotics for USD27 Million 24
Alken Asset Management Sells 2.72% Stake In Grifols For US$227 Million 25
Grifols Completes Acquisition Of 35% Stake In Aradigm For US$26 Million 26
Grifols Acquires 60% Stake In Progenika Biopharma For US$48 Million 27
Grifols SA – Key Competitors 28
Grifols SA – Key Employees 29
Grifols SA – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 34
Strategy And Business Planning 34
Sep 24, 2018: Grifols Announces the Opening of Biotest Pharmaceuticals Corporation’s Newest Plasma Donor Center in Bowling Green, Ohio 34
Nov 22, 2017: Grifols inaugurates a new plant of the Diagnostic Division in Brazil to manufacture storage and collection bags for blood components 35
Financial Announcements 36
Jul 27, 2018: Grifols increases net profits by 15% to EUR 319 million, with sustained operational revenue growth of 7% 36
May 03, 2018: Grifols increases its net profit by 7% to Euros 143 million and delivers significant growth in organic sales 41
Nov 02, 2017: Grifols increases its revenues by 10% to Euros 3,250 million and grows net profit by 6.3% to reach Euros 432 million 44
Jul 28, 2017: Grifols increases its revenues by 12.3% to EUR 2,192 million driven by growth of its main divisions 48
May 03, 2017: Bioscience Division sales increase 15% to drive Grifols’ revenue growth by 11% to Euros 1,062 million 54
Feb 28, 2017: Grifols’ revenues exceed Euros 4,000 million, driven by +6.5% growth of the Bioscience Division 58
Corporate Communications 66
Jul 16, 2018: Grifols has been included in the FTSE4Good Index 66
Legal and Regulatory 67
Jun 08, 2018: Grifols’ Building Receives LEED Certification 67
Mar 19, 2018: Regeneron Pharmaceuticals Announce Regarding Novartis Complaint on ‘688 Patent 68
Other Significant Developments 69
Jul 05, 2018: Grifols, the newest angel of elBullifoundation 69
Jun 28, 2018: Grifols discloses transfers of value made to European healthcare professionals and health-sector organizations in 2017 70
May 25, 2018: Grifols culminates a year of growth and approves the distribution of a record EUR 265 million in dividends 71
May 23, 2018: Grifols publishes its 2017 Corporate Responsibility Report as part of its commitment to transparency 73
Dec 04, 2017: Grifols Misterium Cleanroom Solutions Expands to Include Revolutionary Decontamination Air and Surface Disinfection Systems for Pharmaceutical Preparation 74
Aug 22, 2017: Grifols Phocus Rx Pharmacy Workflow Management Solution Now Integrates With Top Hospital Information Systems via HL7 Interfaces 75
Appendix 76
Methodology 76
About GlobalData 76
Contact Us 76
Disclaimer 76

List of Tables
Grifols SA, Medical Equipment, Key Facts, 2017 2
Grifols SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Grifols SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Grifols SA, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Grifols SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Grifols SA, Deals By Market, 2012 to YTD 2018 9
Grifols SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Grifols Acquires Nucleic Acid Testing Donor Screening Unit from Hologic for USD1.85 Billion 11
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 13
Singulex Enters into Licensing Agreement with Grifols 15
Grifols and Beckman Coulter Enter into Distribution Agreement 16
Grifols Enters Into Licensing Agreement With Aradigm 17
Grifols Invests USD50 Million in Singulex 18
TiGenix Completes Private Placement Of Shares For US$16.2 Million 19
Grifols Raises USD1.06 Billion in Public Offering of 3.2% Bonds Due 2025 20
Grifols Completes Public Offering Of Bonds Due 2022 For US$1 Billion 21
Grifols Acquires Additional 40% Stake in Kiro Grifols for USD15 Million 22
Grifols Acquires Additional 32.93% Stake in Progenika Biopharma for USD27 Million 23
Grifols Acquires 50% Stake in Kiro Robotics for USD27 Million 24
Alken Asset Management Sells 2.72% Stake In Grifols For US$227 Million 25
Grifols Completes Acquisition Of 35% Stake In Aradigm For US$26 Million 26
Grifols Acquires 60% Stake In Progenika Biopharma For US$48 Million 27
Grifols SA, Key Competitors 28
Grifols SA, Key Employees 29
Grifols SA, Other Locations 30
Grifols SA, Subsidiaries 30

List of Figures
Grifols SA, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Grifols SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Grifols SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Grifols SA, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Grifols SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Grifols SA, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Grifols SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Grifols SA, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Grifols SA (GRF):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • St. Jude Medical, Inc.:企業のM&A・事業提携・投資動向
    St. Jude Medical, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's St. Jude Medical, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Capstone Therapeutics Corp (CAPS):企業の財務・戦略的SWOT分析
    Summary Capstone Therapeutics Corp (Capstone), formerly OrthoLogic Corp, is a biotechnology company that develops and sells novel peptides and other molecules for helping patients with under-served medical conditions. The company develops Apo E mimetic peptide molecule AEM-28 and its analogs that ha …
  • BL&H Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary BL&H Co Ltd (BL&H), a subsidiary of STADA Pharmaceuticals (Asia) Ltd is a drug company that manufactures and markets diagnostic test kits and drugs. The company offers products including aridol bronchial challenge test kit, cetraxal plus ear drop, al-sense amniotic leak test kit, DC bead-dru …
  • Cold Spring Harbor Laboratory-製薬・医療分野:企業M&A・提携分析
    Summary Cold Spring Harbor Laboratory (CSHL) is a research and education institution that offers molecular biology and genetics services. The institution’s research services include graduate research, research training, clinical research, quantitative biology research, postdoctoral research, disease …
  • Paysafe Group Plc:企業の戦略的SWOT分析
    Paysafe Group Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • CGI Group Inc.:企業の戦略・SWOT・財務情報
    CGI Group Inc. - Strategy, SWOT and Corporate Finance Report Summary CGI Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • CMA CGM SA:企業の戦略・SWOT・財務情報
    CMA CGM SA - Strategy, SWOT and Corporate Finance Report Summary CMA CGM SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Great Portland Estates Plc (GPOR):企業の財務・戦略的SWOT分析
    Great Portland Estates Plc (GPOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Guardian Industries Corp:企業の戦略的SWOT分析
    Guardian Industries Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Mapi Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Mapi Pharma Ltd (Mapi Pharma) is a clinical stage pharmaceutical company that offers development of active pharmaceutical ingredients and formulations, and life cycle management products. The company’s lead products include Glatiramer Acetate Depot, an injection for the treatment of multiple …
  • Reliance Industries Ltd (RELIANCE):企業の財務・戦略的SWOT分析
    Reliance Industries Ltd (RELIANCE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • LivePerson, Inc. (LPSN):企業の財務・戦略的SWOT分析
    LivePerson, Inc. (LPSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Alere Toxicology Plc:企業の戦略的SWOT分析
    Alere Toxicology Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Innovus Pharmaceuticals Inc (INNV)-製薬・医療分野:企業M&A・提携分析
    Summary Innovus Pharmaceuticals Inc (Innovus Pharmaceuticals), formerly North Horizon Inc is a pharmaceutical company that commercialize, license and develops over-the-counter and consumer healthcare products. The company’s product portfolio comprises BTH testosterone booster; Zestra for female arou …
  • Quark Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Quark Pharmaceuticals Inc (Quark), a subsidiary of SBI Biotech Co Ltd, is a clinical-stage pharmaceutical company in the development of novel RNAi-based therapeutics. It offers under development products which include PF-655, a synthetic siRNA which is used for the treatment of diabetic macu …
  • Schneider Electric SE:企業の戦略・SWOT・財務情報
    Schneider Electric SE - Strategy, SWOT and Corporate Finance Report Summary Schneider Electric SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Genesis Care Pty Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Genesis Care Pty Ltd (Genesis Care) is a healthcare service provider. The company provides radiation oncology, cardiology and sleep treatment services. It offers radiotherapy, intensity modulated radiotherapy, volumetric arc therapy, stereotactic radiotherapy and radiosurgery, low dose rate …
  • Penumbra Inc (PEN):企業の財務・戦略的SWOT分析
    Penumbra Inc (PEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Tactical Missiles Corporation:企業の戦略・SWOT・財務情報
    Tactical Missiles Corporation - Strategy, SWOT and Corporate Finance Report Summary Tactical Missiles Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Volkswagen AG:戦略・SWOT・企業財務分析
    Volkswagen AG - Strategy, SWOT and Corporate Finance Report Summary Volkswagen AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆